Practice patterns for reporting digestive system neuroendocrine neoplasms: results from a large, comprehensive international survey.
gastrointestinal tract
neuroendocrine
pathology
survey
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
revised:
05
12
2022
received:
25
09
2022
accepted:
08
12
2022
pubmed:
13
12
2022
medline:
10
2
2023
entrez:
12
12
2022
Statut:
ppublish
Résumé
Criteria for the interpretation of digestive system neuroendocrine neoplasms (NENs) continue to evolve. Although there are some literature recommendations regarding workup and diagnosis of these lesions, different practice patterns exist among pathologists when signing out these specimens. The aim of this study was to assess practice trends among pathologists worldwide when reporting these neoplasms. We created an online survey with multiple questions pertaining to digestive NENs. The results were analysed based on type of practice setting, years of sign-out experience, and practice location. Respondents included 384 practicing pathologists: 70% academic, 30% private practice; 63% gastrointestinal (GI) pathology-subspecialised, 37% not; 39% North American, 42% European, 19% others; 45% with ≤10 years in practice; 55% with >10 years. Some question responses were chosen by the majority (e.g. 85% use both mitotic count and Ki67 index for grading NENs, 82% complete a synoptic, and Ki67 stain even for small incidental appendiceal neuroendocrine tumours [NETs], and 96% utilize the diagnosis of grade 3 NET). However, some questions showed varying responses, including counting mitotic figures, Ki67 stain interpretation, and pancreatic grade 3 NEN workup. Pathologists also had some variability in interpreting regional metastatic foci of small bowel NETs and in choosing blocks for Ki67 staining in multifocal lesions. There existed scenarios wherein practice patterns varied despite recommendations in the literature, and there were also scenarios lacking clear guidelines wherein pathologists used varying judgement. This survey highlights current key grey areas in digestive system NEN evaluation, leading to variation in practice patterns.
Substances chimiques
Ki-67 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
541-554Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Klimstra DS, Klöppel G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. InWHO classification of tumours editorial board. Digestive system tumours. 5th ed. Lyon, France: IARC, 2019; 16-19.
Rindi G, Klimstra DS, Abedi-Ardekani B et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod. Pathol. 2018; 31; 1770-1786.
Rindi G, Mete O, Uccella S et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr. Pathol. 2022; 33; 115-154.
Gonzalez RS. Diagnosis and management of gastrointestinal neuroendocrine neoplasms. Surg Pathol. Clin. 2020; 13; 377-397.
Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch. 2018; 472; 341-349.
Brierly JD, Gospodarowicz MK, Wittekind C. Well-differentiated neuroendocrine tumours - pancreas (G1 and G2). InUICC TNM classification of malignant Tumours. New Jersey: Wiley Blackwell, 2018; 102-103.
Bergsland EK, Woltering EA, Rindi G, O'Dorisio TM, Schilsky RL, Liu EH, Kim MK, Nakakura EK, Reidy-Lagunes DL, Strosberg JR, Tang LH, Vinik AI, Wang YZ, Asare EA, Brierley JD, Bushnell DL, Jensen RT, Pommier RF, Wolin EM, Wong RKS, Klimstra DS Neuroendocrine tumors of the pancreas. In Amin MB, Edge SB, Greene FL, Schilsky RL, Gaspar LE, Washington MK et al, eds. AJCC cancer staging manual . 8th ed. New York, NY: Springer; 2017; 407-419.
Woltering E, Bergsland EK, Beyer DT et al. Neuroendocrine tumors of the jejunum and ileum. In Amin MB, Edge SB, Greene FL et al. eds. AJCC cancer staging manual. 8th ed. New York, NY: Springer, 2017; 375-387.
Niederle B, Pape UF, Costa F et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology 2016; 103; 125-138.
Pape UF, Niederle B, Costa F et al. ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas). Neuroendocrinology 2016; 103; 144-152.
Delle Fave G, O'Toole D, Sundin A et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology 2016; 103; 119-124.
Ramage JK, De Herder WW, Delle Fave G et al. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology 2016; 103; 139-143.
Falconi M, Eriksson B, Kaltsas G et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 2016; 103; 153-171.
Garcia-Carbonero R, Sorbye H, Baudin E et al. ENETS consensus guidelines for high-grade Gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology 2016; 103; 186-194.
O'Toole D, Kianmanesh R, Caplin M. ENETS 2016 consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update. Neuroendocrinology 2016; 103; 117-118.
van Velthuysen MF, Couvelard A, Rindi G et al. ENETS standardised (synoptic) reporting for neuroendocrine tumour pathology. J. Neuroendocrinol. 2022; 34; e13100.
Perren A, Couvelard A, Scoazec JY et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology 2017; 105; 196-200.
Klöppel G, Adsay NV, Couvelard A et al. Pancreatic neuroendocrine neoplasms: introduction. InWHO classification of tumours editorial board. Digestive system tumours. 5th ed. Lyon, France: IARC, 2019; 343-346.
Pelosi G, Rindi G, Travis WD, Papotti M. Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J. Thorac. Oncol. 2014; 9; 273-284.
Reid MD, Bagci P, Ohike N et al. Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Mod. Pathol. 2015; 28; 686-694.
Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am. J. Surg. Pathol. 2016; 40; 1192-1202.
Adsay V. Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count. Am. J. Surg. Pathol. 2012; 36; 1743-1746.
Reid MD, Balci S, Saka B, Adsay NV. Neuroendocrine tumors of the pancreas: current concepts and controversies. Endocr. Pathol. 2014; 25; 65-79.
Kim JY, Hong SM. Recent updates on neuroendocrine tumors from the gastrointestinal and pancreatobiliary tracts. Arch. Pathol. Lab. Med. 2016; 140; 437-448.
Bellizzi AM. Pathologic considerations in gastroenteropancreatic neuroendocrine tumors. Surg. Oncol. Clin. N. Am. 2020; 29; 185-208.
Bellizzi AM. Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you? Hum. Pathol. 2020; 96; 8-33.
Rosenbaum JN, Guo Z, Baus RM, Werner H, Rehrauer WM, Lloyd RV. INSM1: a novel immunohistochemical and molecular marker for neuroendocrine and neuroepithelial neoplasms. Am. J. Clin. Pathol. 2015; 144; 579-591.
Rooper LM, Sharma R, Li QK, Illei PB, Westra WH. INSM1 demonstrates superior performance to the individual and combined use of synaptophysin, chromogranin and CD56 for diagnosing neuroendocrine tumors of the thoracic cavity. Am. J. Surg. Pathol. 2017; 41; 1561-1569.
Gonzalez RS, Cates JMM, Shi C. Number, not size, of mesenteric tumor deposits affects prognosis of small intestinal well-differentiated neuroendocrine tumors. Mod. Pathol. 2018; 31; 1560-1566.
Gonzalez RS, Liu EH, Alvarez JR, Ayers GD, Washington MK, Shi C. Should mesenteric tumor deposits be included in staging of well-differentiated small intestine neuroendocrine tumors? Mod. Pathol. 2014; 27; 1288-1295.
Panzuto F, Campana D, Fazio N et al. Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. Neuroendocrinology 2012; 96; 32-40.
Strosberg JR, Weber JM, Feldman M, Coppola D, Meredith K, Kvols LK. Prognostic validity of the American Joint Committee on cancer staging classification for midgut neuroendocrine tumors. J. Clin. Oncol. 2013; 31; 420-425.
Cunningham JL, Grimelius L, Sundin A, Agarwal S, Janson ET. Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis. Acta Oncol. 2007; 46; 747-756.
Ahmed A, Turner G, King B et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr. Relat. Cancer 2009; 16; 885-894.
Numbere N, Huber AR, Shi C, Cates JMM, Gonzalez RS. Should Ki67 immunohistochemistry be performed on all lesions in multifocal small intestinal neuroendocrine tumours? Histopathology 2019; 74; 424-429.
Shi C, Gonzalez RS, Zhao Z et al. Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. Am. J. Clin. Pathol. 2015; 143; 398-404.
Zen Y, Heaton N. Elevated Ki-67 labeling index in ‘synchronous liver metastases’ of well differentiated enteropancreatic neuroendocrine tumor. Pathol. Int. 2013; 63; 532-538.
Grillo F, Albertelli M, Brisigotti MP et al. Grade increases in gastroenteropancreatic neuroendocrine tumor metastases compared to the primary tumor. Neuroendocrinology 2016; 103; 452-459.
Keck KJ, Choi A, Maxwell JE et al. Increased grade in neuroendocrine tumor metastases negatively impacts survival. Ann. Surg. Oncol. 2017; 24; 2206-2212.
Fata CR, Gonzalez RS, Liu E, Cates JM, Shi C. Mesenteric tumor deposits in midgut small intestinal neuroendocrine tumors are a stronger indicator than lymph node metastasis for liver metastasis and poor prognosis. Am. J. Surg. Pathol. 2017; 41; 128-133.
Sun Y, Lohse C, Smyrk T, Hobday T, Kroneman T, Zhang L. The influence of tumor stage on the prognostic value of Ki-67 index and mitotic count in small intestinal neuroendocrine tumors. Am. J. Surg. Pathol. 2018; 42; 247-255.
Polydorides AD, Liu Q. Evaluation of pathologic prognostic factors in neuroendocrine tumors of the small intestine. Am. J. Surg. Pathol. 2022; 46; 547-556.
Jessup JM, Goldberg RM, Asare EA et al. Colon and rectum. In Amin MB, Edge SB, Greene FL et al. eds. AJCC cancer staging manual. 8th ed. New York, NY: Springer, 2017; 251-274.
Rock JB, Washington MK, Adsay NV et al. Debating deposits: an interobserver variability study of lymph nodes and pericolonic tumor deposits in colonic adenocarcinoma. Arch. Pathol. Lab. Med. 2014; 138; 636-642.
Noor M, Huber AR, Cates JMM, Gonzalez RS. Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation. Histopathology 2021; 79; 416-426.
Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. N. Engl. J. Med. 1987; 317; 1699-1701.
Rault-Petit B, Do Cao C, Guyetant S et al. Current management and predictive factors of lymph node metastasis of appendix neuroendocrine tumors: a National Study from the French Group of Endocrine Tumors (GTE). Ann. Surg. 2019; 270; 165-171.
Brighi N, La Rosa S, Rossi G et al. Morphological factors related to nodal metastases in neuroendocrine tumors of the appendix: a multicentric retrospective study. Ann. Surg. 2020; 271; 527-533.
Volante M, Daniele L, Asioli S et al. Tumor staging but not grading is associated with adverse clinical outcome in neuroendocrine tumors of the appendix: a retrospective clinical pathologic analysis of 138 cases. Am. J. Surg. Pathol. 2013; 37; 606-612.
Fang JM, Shi J. A clinicopathologic and molecular update of pancreatic neuroendocrine neoplasms with a focus on the New World Health Organization Classification. Arch. Pathol. Lab. Med. 2019; 143; 1317-1326.
Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann. Oncol. 2008; 19; 1727-1733.
Lam AK, Ishida H. Pancreatic neuroendocrine neoplasms: clinicopathological features and pathological staging. Histol. Histopathol. 2021; 36; 367-382.
Guilmette JM, Nose V. Neoplasms of the neuroendocrine pancreas: an update in the classification, definition, and molecular genetic advances. Adv. Anat. Pathol. 2019; 26; 13-30.
Konukiewitz B, Jesinghaus M, Kasajima A, Kloppel G. Neuroendocrine neoplasms of the pancreas: diagnosis and pitfalls. Virchows Arch. 2022; 480; 247-257.
Fuchs TL, Chou A, Ahadi M et al. Necrosis is an independent predictor of disease-free and overall survival in pancreatic well-differentiated neuroendocrine tumours (NETs): a proposal to include it in grading systems. Pathology 2022; 54; 855-862.
Demir R, Pohl J, Agaimy A et al. Necrosis and angioinvasion predict adverse outcome in pancreatic neuroendocrine tumors after curative surgical resection: results of a single-center series. World J. Surg. 2011; 35; 2764-2772.
La Rosa S, Solcia E. New insights into the classification of gastric neuroendocrine tumours, expanding the spectrum of ECL-cell tumours related to hypergastrinaemia. Histopathology 2020; 77; 862-864.
La Rosa S, Inzani F, Vanoli A et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum. Pathol. 2011; 42; 1373-1384.
Rindi G, Azzoni C, La Rosa S et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999; 116; 532-542.
Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993; 104; 994-1006.
Vanoli A, La Rosa S, Miceli E et al. Prognostic evaluations tailored to specific gastric neuroendocrine neoplasms: analysis of 200 cases with extended follow-up. Neuroendocrinology 2018; 107; 114-126.
Mastracci L, Rindi G, Grillo F et al. Neuroendocrine neoplasms of the esophagus and stomach. Pathologica 2021; 113; 5-11.
Bloomquist MS, Powell J 3rd, Masand RP, Dhall D, Karamchandani DM, Jain S. Lack of uniformity in reporting autoimmune gastritis among a diverse group of pathologists. Ann. Diagn. Pathol. 2022; 56; 151840.
Chai SM, Brown IS, Kumarasinghe MP. Gastroenteropancreatic neuroendocrine neoplasms: selected pathology review and molecular updates. Histopathology 2018; 72; 153-167.
Solcia E, Arnold R, Capelia C et al. Neuroendocrine neoplasms of the stomach. In Bosman FT, Carneiro F, Hruban RH, Theise ND eds. WHO classification of tumours of the digestive system tumours. 4th ed. Lyon, France: IARC Press, 2010; 64-68.
La Rosa S, Rindi G, Solcia E, Tang LH. Gastric neuroendocrine neoplasms. InWHO classification of tumours editorial board. Digestive system tumours. 5th ed. Lyon, France: IARC, 2019; 104-109.
Burgart LJ, Chopp WV, Jain D. Protocol for the Examination of Specimens from Patients with Well-Differentiated Neuroendocrine Tumors (Carcinoid Tumors) of the Stomach 2021 [Version 4.1.0.0. Protocol posting Date June 2021]. Available at: https://documents.cap.org/protocols/Stomach.NET_4.1.0..REL_CAPCP.pdf